Kairos Pharma
Most recent annual filing: 2026-03-31
- ENV-105 lung Ph1 interim2026ENV-105 lung Ph1 interim, 2026, material
- NCT05534646 readout4Q 2027NCT05534646 readout, 4Q 2027, notable
- Enviro-Cedars license BLA filingJun 2028Enviro-Cedars license BLA filing, Jun 2028, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (13 active programs)
ENV 105
ENV 205
Protein Target: mitochondrial DNA
KROS 101
Small Molecule Target: GITR ligand, GITRL, GITR
- Undisclosed indication
KROS 102
Small Molecule Target: GITR
- Undisclosed indication
KROS 201
Cell Target: cancer stem cells
KROS 301
Small Molecule Target: RelA, NF-KB
- Undisclosed indication
KROS 401
Peptide Target: IL-4, IL-13, IL13R alpha1, IL4R alpha1
CL-273
Target: EGFR
CL-741
Target: c-MET
Biotech Distilled coverage (2)
- 2026-10-07 UPDATE: Kairos Pharma (KAPA) - The Control Arm Finally Shows Up ★ Distilled Pro
- 2026-08-18 Kairos Pharma (KAPA) - Scientific Deep Dive for ENV-105 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.